616 related articles for article (PubMed ID: 28964430)
1. Good Practices for Real-World Data Studies of Treatment and/or Comparative Effectiveness: Recommendations from the Joint ISPOR-ISPE Special Task Force on Real-World Evidence in Health Care Decision Making.
Berger ML; Sox H; Willke RJ; Brixner DL; Eichler HG; Goettsch W; Madigan D; Makady A; Schneeweiss S; Tarricone R; Wang SV; Watkins J; Mullins CD
Value Health; 2017 Sep; 20(8):1003-1008. PubMed ID: 28964430
[TBL] [Abstract][Full Text] [Related]
2. Good practices for real-world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making.
Berger ML; Sox H; Willke RJ; Brixner DL; Eichler HG; Goettsch W; Madigan D; Makady A; Schneeweiss S; Tarricone R; Wang SV; Watkins J; Daniel Mullins C
Pharmacoepidemiol Drug Saf; 2017 Sep; 26(9):1033-1039. PubMed ID: 28913966
[TBL] [Abstract][Full Text] [Related]
3. Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing-Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative.
Orsini LS; Berger M; Crown W; Daniel G; Eichler HG; Goettsch W; Graff J; Guerino J; Jonsson P; Lederer NM; Monz B; Mullins CD; Schneeweiss S; Brunt DV; Wang SV; Willke RJ
Value Health; 2020 Sep; 23(9):1128-1136. PubMed ID: 32940229
[TBL] [Abstract][Full Text] [Related]
4. The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report.
McGhan WF; Al M; Doshi JA; Kamae I; Marx SE; Rindress D
Value Health; 2009; 12(8):1086-99. PubMed ID: 19744291
[TBL] [Abstract][Full Text] [Related]
5. Improving transparency to build trust in real-world secondary data studies for hypothesis testing-Why, what, and how: recommendations and a road map from the real-world evidence transparency initiative.
Orsini LS; Monz B; Mullins CD; Van Brunt D; Daniel G; Eichler HG; Graff J; Guerino J; Berger M; Lederer NM; Jonsson P; Schneeweiss S; Wang SV; Crown W; Goettsch W; Willke RJ
Pharmacoepidemiol Drug Saf; 2020 Nov; 29(11):1504-1513. PubMed ID: 32924243
[TBL] [Abstract][Full Text] [Related]
6. HARmonized Protocol Template to Enhance Reproducibility of hypothesis evaluating real-world evidence studies on treatment effects: A good practices report of a joint ISPE/ISPOR task force.
Wang SV; Pottegård A; Crown W; Arlett P; Ashcroft DM; Benchimol EI; Berger ML; Crane G; Goettsch W; Hua W; Kabadi S; Kern DM; Kurz X; Langan S; Nonaka T; Orsini L; Perez-Gutthann S; Pinheiro S; Pratt N; Schneeweiss S; Toussi M; Williams RJ
Pharmacoepidemiol Drug Saf; 2023 Jan; 32(1):44-55. PubMed ID: 36215113
[TBL] [Abstract][Full Text] [Related]
7. HARmonized Protocol Template to Enhance Reproducibility of Hypothesis Evaluating Real-World Evidence Studies on Treatment Effects: A Good Practices Report of a Joint ISPE/ISPOR Task Force.
Wang SV; Pottegård A; Crown W; Arlett P; Ashcroft DM; Benchimol EI; Berger ML; Crane G; Goettsch W; Hua W; Kabadi S; Kern DM; Kurz X; Langan S; Nonaka T; Orsini L; Perez-Gutthann S; Pinheiro S; Pratt N; Schneeweiss S; Toussi M; Williams RJ
Value Health; 2022 Oct; 25(10):1663-1672. PubMed ID: 36241338
[TBL] [Abstract][Full Text] [Related]
8. The joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making: an interview with Marc Berger.
Berger ML
J Comp Eff Res; 2018 Jan; 7(1):11-13. PubMed ID: 29052427
[TBL] [Abstract][Full Text] [Related]
9. Developing Patient-Centered Real-World Evidence: Emerging Methods Recommendations From a Consensus Process.
Oehrlein EM; Schoch S; Burcu M; McBeth JF; Bright J; Pashos CL; Willke R; Love TR; Mattingly TJ; Perfetto EM;
Value Health; 2023 Jan; 26(1):28-38. PubMed ID: 35863944
[TBL] [Abstract][Full Text] [Related]
10. Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report.
Garrison LP; Neumann PJ; Erickson P; Marshall D; Mullins CD
Value Health; 2007; 10(5):326-35. PubMed ID: 17888097
[TBL] [Abstract][Full Text] [Related]
11. Prospective observational studies to assess comparative effectiveness: the ISPOR good research practices task force report.
Berger ML; Dreyer N; Anderson F; Towse A; Sedrakyan A; Normand SL
Value Health; 2012; 15(2):217-30. PubMed ID: 22433752
[TBL] [Abstract][Full Text] [Related]
12. Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report--Part I.
Berger ML; Mamdani M; Atkins D; Johnson ML
Value Health; 2009; 12(8):1044-52. PubMed ID: 19793072
[TBL] [Abstract][Full Text] [Related]
13. Good research practices for comparative effectiveness research: approaches to mitigate bias and confounding in the design of nonrandomized studies of treatment effects using secondary data sources: the International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report--Part II.
Cox E; Martin BC; Van Staa T; Garbe E; Siebert U; Johnson ML
Value Health; 2009; 12(8):1053-61. PubMed ID: 19744292
[TBL] [Abstract][Full Text] [Related]
14. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force.
Husereau D; Drummond M; Petrou S; Carswell C; Moher D; Greenberg D; Augustovski F; Briggs AH; Mauskopf J; Loder E;
Value Health; 2013; 16(2):231-50. PubMed ID: 23538175
[TBL] [Abstract][Full Text] [Related]
15. Recommendations on evidence needed to support measurement equivalence between electronic and paper-based patient-reported outcome (PRO) measures: ISPOR ePRO Good Research Practices Task Force report.
Coons SJ; Gwaltney CJ; Hays RD; Lundy JJ; Sloan JA; Revicki DA; Lenderking WR; Cella D; Basch E;
Value Health; 2009 Jun; 12(4):419-29. PubMed ID: 19900250
[TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness research: guidelines for good practices are just the beginning.
Johnson ML; Chitnis AS
Expert Rev Pharmacoecon Outcomes Res; 2011 Feb; 11(1):51-7. PubMed ID: 21351858
[TBL] [Abstract][Full Text] [Related]
17. Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--1.
Caro JJ; Briggs AH; Siebert U; Kuntz KM;
Value Health; 2012; 15(6):796-803. PubMed ID: 22999128
[TBL] [Abstract][Full Text] [Related]
18. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report.
Ramsey S; Willke R; Briggs A; Brown R; Buxton M; Chawla A; Cook J; Glick H; Liljas B; Petitti D; Reed S
Value Health; 2005; 8(5):521-33. PubMed ID: 16176491
[TBL] [Abstract][Full Text] [Related]
19. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.
Sullivan SD; Mauskopf JA; Augustovski F; Jaime Caro J; Lee KM; Minchin M; Orlewska E; Penna P; Rodriguez Barrios JM; Shau WY
Value Health; 2014; 17(1):5-14. PubMed ID: 24438712
[TBL] [Abstract][Full Text] [Related]
20. Selecting a dynamic simulation modeling method for health care delivery research-part 2: report of the ISPOR Dynamic Simulation Modeling Emerging Good Practices Task Force.
Marshall DA; Burgos-Liz L; IJzerman MJ; Crown W; Padula WV; Wong PK; Pasupathy KS; Higashi MK; Osgood ND;
Value Health; 2015 Mar; 18(2):147-60. PubMed ID: 25773550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
